Skip to main content
. Author manuscript; available in PMC: 2017 Apr 15.
Published in final edited form as: Cancer Res. 2016 Feb 15;76(8):2125–2136. doi: 10.1158/0008-5472.CAN-15-1490

Figure 1. Murine and human MDSC express BTK and its phosphorylation is inhibited by ibrutinib.

Figure 1

(A) Immunoblot showing BTK and GAPDH expression in MDSC isolated from the spleen of mice bearing 4T1 and EMT6 mammary carcinoma tumors. (B) Immunoblot of BTK and GAPDH expression in human MDSC isolated from patients with metastatic melanoma and in vitro generated MDSC. Results displayed are from two separate immunoblots. (C) Immunoblot showing ibrutinib reduces the level of phosphorylated BTK (p-BTK) in LPS stimulated MSC2 cells. (D) In vitro generated MDSC were treated with DMSO or ibrutinib for 1 hour followed by stimulation with IL-6 and GM-CSF. Lysates were collected 15 minutes after stimulation and probed for expression of p-BTK, BTK, and GAPDH.